Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are currently a part of the Ohio State portfolio or download our printable catalog (as of June 30, 2019).
Search for a Startup below
Sirona Therapeutics is commercializing an oral patch that delivers chemopreventive drugs directly to pre-cancerous oral lesions, reducing toxicity and adverse side effects.
Prelude Therapeutics is focused on the discovery and development of differentiated small-molecule drugs targeting gene regulation for cancer and rare diseases.
OncoImmune specializes in therapeutics for cancer, inflammation and autoimmune diseases. OncoImmune’s lead compound CD24Fc is a clinical stage asset targeting the CD24-Siglec axis that regulates host inflammatory response to tissue injuries. This has broad implications in the pathogenesis of autoimmune diseases, cancer and graft-versus-host disease. OncoImmune has received orphan drug designation for CD24Fc in both the United States and Europe.
NeurXStem produces synthetic neural organoids from iPSC-derived skin cells that closely replicate the human central nervous system in a dish. This Neural Organoid Platform™ meets high scientific metrics of reliability, reproducibility and robustness. This makes the platform highly suitable for pre-clinical research and development to identify and evaluate potential drugs for toxicity, safety and efficacy on model systems that accurately mimic human functions.
NervGen Pharma Corp. is a regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of nerve damage, including spinal cord and peripheral nerve injuries. The company’s technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that inhibits nerve regeneration. Inhibition of the PTPσ receptor promotes regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions.